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Abstract 
 
Congenital heart defects (CHDs) occur in approximately one percent of births every year 
(American Heart Association, 2008). This makes it the most frequently occurring congenital 
defect in humans. My research is aimed at using two mutant cardiac neural crest (CNC) mouse 
models to study the mechanisms underlying congenital heart failure in utero with particular 
interests in understanding the processes of outflow tract (OFT) septation and myocardial 
homeostasis. The first mouse model is a Pax3 systemic knockout, which is lethal by mouse 
gestational day14, and has an insufficient number of migratory CNC cells. The second mouse 
model is a Wnt1Cre-mediated neural crest-ablated model, which is surprisingly viable and 
survives to birth, despite having no migratory CNC cells.  
My data indicates that both mouse models have similar heart structural anomalies including 
failure of the OFT to divide and interventricular septation defects. However, in utero heart 
function is significantly perturbed in Pax3 mutants when compared to that of the ablated mutant 
model. Via comparison of these two mutant mouse models, I have been able to assess the tissue-
specific contribution of the CNC cell lineage during in utero heart morphogenesis, as well as to 
identify the beta-adrenergic pathway as the underlying mechanistic pathway that is important for 
the observed differences in myocardial function and subsequent congenital heart failure and 
lethality in the Pax3 mutants. By doing so, I am now able to demonstrate pharmacological rescue 
of the Pax3 mutants to birth, via bypassing or stimulation of the aforementioned pathway. 
By understanding the causes of congenital heart failure and subsequent lethality in the Pax3 
genetic model, and successfully achieving pharmacological rescue to birth, I believe the results 
of my project will allow me to translate my findings into better treatment strategies for newborn 
patients with similar CHDs. 
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